DOP2022000099A - Antagonistas heterocíclicos de nmda - Google Patents
Antagonistas heterocíclicos de nmdaInfo
- Publication number
- DOP2022000099A DOP2022000099A DO2022000099A DO2022000099A DOP2022000099A DO P2022000099 A DOP2022000099 A DO P2022000099A DO 2022000099 A DO2022000099 A DO 2022000099A DO 2022000099 A DO2022000099 A DO 2022000099A DO P2022000099 A DOP2022000099 A DO P2022000099A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- nmda antagonists
- heterocyclic
- heterocyclic nmda
- migraine
- dementia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de la fórmula (I): (I), o una sal del mismo que puede tener una acción antagonista contra un receptor NMDA que incluye una subunidad NR2B y puede ser útil como agente profiláctico o terapéutico para la depresión, trastorno bipolar, migraña, dolor, un síntoma periférico de la demencia o similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019206311A JP2021080177A (ja) | 2019-11-14 | 2019-11-14 | 複素環化合物及びその用途 |
PCT/IB2020/000962 WO2021094832A1 (en) | 2019-11-14 | 2020-11-12 | Heterocyclic nmda antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2022000099A true DOP2022000099A (es) | 2022-08-31 |
Family
ID=74141594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000099A DOP2022000099A (es) | 2019-11-14 | 2022-05-13 | Antagonistas heterocíclicos de nmda |
Country Status (20)
Country | Link |
---|---|
US (3) | US20230002318A1 (es) |
EP (1) | EP4058430A1 (es) |
JP (2) | JP2021080177A (es) |
KR (1) | KR20220102629A (es) |
CN (1) | CN114728900A (es) |
AR (1) | AR120452A1 (es) |
AU (1) | AU2020385250A1 (es) |
BR (1) | BR112022008367A2 (es) |
CA (1) | CA3158352A1 (es) |
CL (1) | CL2022001241A1 (es) |
CO (1) | CO2022008012A2 (es) |
CR (1) | CR20220275A (es) |
DO (1) | DOP2022000099A (es) |
EC (1) | ECSP22037602A (es) |
IL (1) | IL292639A (es) |
JO (1) | JOP20220108A1 (es) |
MX (1) | MX2022005778A (es) |
PE (1) | PE20221767A1 (es) |
TW (1) | TW202132268A (es) |
WO (1) | WO2021094832A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE298765T1 (de) | 1996-08-27 | 2005-07-15 | Praecis Pharm Inc | Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren |
US6420415B1 (en) * | 1998-09-21 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Thiol compounds, their production and use |
CA2374346C (en) | 1999-06-28 | 2010-06-22 | Jordan J. N. Tang | Inhibitors of memapsin 2 and use thereof |
EP1235572A2 (en) * | 1999-10-29 | 2002-09-04 | MERCK SHARP & DOHME LTD. | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
EP1500658A4 (en) * | 2002-04-26 | 2007-04-11 | Takeda Pharmaceutical | NEW THIOL DERIVATIVE, METHOD FOR ITS PRODUCTION AND ITS USE |
AR057218A1 (es) * | 2005-12-15 | 2007-11-21 | Astra Ab | Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
EP3110434B1 (en) | 2014-02-24 | 2018-09-19 | Takeda GmbH | Uti fusion proteins |
WO2018205935A1 (zh) | 2017-05-09 | 2018-11-15 | 浙江大学 | 治疗抑郁症的方法和药物组合物 |
JP6806735B2 (ja) | 2018-05-30 | 2021-01-06 | 矢崎総業株式会社 | 車両用回路体および車両用回路体の製造方法 |
MX2021004427A (es) | 2018-10-18 | 2021-11-12 | Univ British Columbia | Moduladores del receptor de andrógenos y métodos para su uso. |
JP2022521824A (ja) | 2019-03-28 | 2022-04-12 | エッサ ファーマ,インコーポレイテッド | アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用 |
JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
-
2019
- 2019-11-14 JP JP2019206311A patent/JP2021080177A/ja active Pending
-
2020
- 2020-11-12 JP JP2022527713A patent/JP2023502030A/ja active Pending
- 2020-11-12 AU AU2020385250A patent/AU2020385250A1/en active Pending
- 2020-11-12 CA CA3158352A patent/CA3158352A1/en active Pending
- 2020-11-12 AR ARP200103139A patent/AR120452A1/es unknown
- 2020-11-12 KR KR1020227019888A patent/KR20220102629A/ko unknown
- 2020-11-12 EP EP20838595.5A patent/EP4058430A1/en active Pending
- 2020-11-12 JO JOP/2022/0108A patent/JOP20220108A1/ar unknown
- 2020-11-12 CR CR20220275A patent/CR20220275A/es unknown
- 2020-11-12 BR BR112022008367A patent/BR112022008367A2/pt unknown
- 2020-11-12 CN CN202080079710.1A patent/CN114728900A/zh active Pending
- 2020-11-12 TW TW109139608A patent/TW202132268A/zh unknown
- 2020-11-12 MX MX2022005778A patent/MX2022005778A/es unknown
- 2020-11-12 PE PE2022000751A patent/PE20221767A1/es unknown
- 2020-11-12 WO PCT/IB2020/000962 patent/WO2021094832A1/en active Application Filing
- 2020-11-12 US US17/755,907 patent/US20230002318A1/en active Pending
-
2022
- 2022-05-01 IL IL292639A patent/IL292639A/en unknown
- 2022-05-12 CL CL2022001241A patent/CL2022001241A1/es unknown
- 2022-05-12 EC ECSENADI202237602A patent/ECSP22037602A/es unknown
- 2022-05-13 DO DO2022000099A patent/DOP2022000099A/es unknown
- 2022-06-06 CO CONC2022/0008012A patent/CO2022008012A2/es unknown
- 2022-12-22 US US18/087,302 patent/US11827601B2/en active Active
- 2022-12-22 US US18/087,233 patent/US11834409B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CR20220275A (es) | 2023-02-17 |
CL2022001241A1 (es) | 2023-02-03 |
US11827601B2 (en) | 2023-11-28 |
KR20220102629A (ko) | 2022-07-20 |
MX2022005778A (es) | 2022-06-09 |
IL292639A (en) | 2022-07-01 |
EP4058430A1 (en) | 2022-09-21 |
US20230002318A1 (en) | 2023-01-05 |
WO2021094832A8 (en) | 2022-06-02 |
CA3158352A1 (en) | 2021-05-20 |
BR112022008367A2 (pt) | 2022-10-18 |
US11834409B2 (en) | 2023-12-05 |
JOP20220108A1 (ar) | 2023-01-30 |
CN114728900A (zh) | 2022-07-08 |
JP2021080177A (ja) | 2021-05-27 |
JP2023502030A (ja) | 2023-01-20 |
US20230134307A1 (en) | 2023-05-04 |
WO2021094832A1 (en) | 2021-05-20 |
ECSP22037602A (es) | 2022-06-30 |
TW202132268A (zh) | 2021-09-01 |
PE20221767A1 (es) | 2022-11-11 |
US20230150934A1 (en) | 2023-05-18 |
AR120452A1 (es) | 2022-02-16 |
CO2022008012A2 (es) | 2022-06-10 |
AU2020385250A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022008012A2 (es) | Antagonistas heterocíclicos de nmda | |
PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
EA202091506A1 (ru) | Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa | |
MX2022007085A (es) | Nanoemulsion para uso oral. | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
BR112018011154A2 (pt) | dispersões sólidas compreendendo um estimulador de sgc | |
PH12019502676A1 (en) | Moisturizing topical preparation | |
MX2019006904A (es) | Composicion para el cuidado bucal y metodos para blanquear los dientes. | |
MX2021001209A (es) | Composiciones oleaginosas topicas. | |
MX2022007391A (es) | Compuestos activos frente a receptores nucleares. | |
MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
GEP20186908B (en) | P-substituted asymmetric ureas and medical uses thereof | |
AU2019241765A8 (en) | Heterocyclic compound and use thereof | |
EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
BR112018074162A2 (pt) | composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica. | |
MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
UA122811C2 (uk) | Фармацевтична композиція | |
GEP20227354B (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
WO2021011874A8 (en) | Ghrh antagonists for use in a method of treating sarcoidosis | |
SV2017005527A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
PL426157A1 (pl) | Zastosowanie medyczne 4-(2-fluorofenylo)-1-(4-metyloimidazol-5-ilo)tiosemikarbazydu | |
TN2016000561A1 (en) | Stabilized desmopressin | |
EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |